Video
Dr. Bendell on the Next Steps Following Progression on Immunotherapy in MSI-H CRC
Author(s):
Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the next steps following progression on checkpoint inhibitors in microsatellite instability-high (MSI-H) colorectal cancer (CRC).
Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the next steps following progression on checkpoint inhibitors in microsatellite instability-high (MSI-H) colorectal cancer (CRC).
For patients with MSI-H disease, they can still have the general standard chemotherapies that are still available to them, as well as targeted agents following progression on checkpoint inhibitor therapy, explains Bendell.
If a patient progresses on the checkpoint inhibitor, they could potentially go on to regorafenib (Stivarga), TAS-102 (Lonsurf), or a clinical trial. According to Bendell, there are many clinical trials that are looking at combinations for patients who have progressive disease following single-agent immunotherapies.
